news-med.jpg

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives

New research by Cyprotex in the field of metformin drug-drug interactions has been published in Pharmacology Research & Perspectives. The publication assists in further understanding the mechanism behind clinically observed DDIs with the common co-medication, metformin. Read our blog and download ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec and Tesaro Enter Strategic Partnership To Discover Novel Immuno-Oncology Agents

Discovery and development of inhibitors against Tesaro's Immuno-Oncology target utilising Evotec's comprehensive discovery and development platform Hamburg, Germany, 26 October 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a ...

Topics: Corporate, Drug Development, Drug Discovery Read More

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion ...

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

Topics: Corporate, Acquisition, Drug Development, Drug Discovery, Contract Reseach Organization, Partner Research Organization, Integrated CMC, IND Enabling Read More

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations

Greenwich, CT, April 6, 2017 – Jonathan Goldman, CEO of Aptuit LLC, announced today that Henning Steinhagen, PhD, has been named as President, Research and Development Operations. Henning will continue in his existing role of Site-Head at Aptuit, Verona, Italy whilst assuming oversight of Aptuit ...

Topics: Corporate, Partner Research Organization Read More

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s ...

Topics: Strategy, Corporate, Business, Drug design and discovery Read More

Aptuit announces drug discovery collaboration with Massachusetts General Hospital (MGH) to identify novel treatments for Gram-negative infections

Greenwich, CT - January 24, 2017 - Aptuit, LLC today announced the start of a collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH), directed by Dr. Laurence Rahme, aimed at the identification and validation of novel targets in Gram-negative bacteria. Aptuit ...

Topics: Corporate, Drug design and discovery Read More

Chronos Therapeutics partners with Aptuit for addictive behaviour programmes

Oxford, UK - January 9, 2017 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting ...

Topics: Corporate, Business Read More

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis

Greenwich, CT, and Parma, Italy – January 4, 2017 Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated ...

Topics: Corporate, Business, Drug design and discovery Read More